



**QUEEN'S  
UNIVERSITY  
BELFAST**

## **Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: an analysis of two independent population-based databases**

Spence, A., Busby, J., Murchie, P., Kunzmann, A., McMenamin, U., Coleman, H., Johnston, B. T., O'Rourke, M., Murray, L., Iversen, L., Lee, A. J., & Cardwell, C. (2018). Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: an analysis of two independent population-based databases. *International Journal of Cancer*, 143(1). <https://doi.org/10.1002/ijc.31293>

**Published in:**  
International Journal of Cancer

**Document Version:**  
Peer reviewed version

**Queen's University Belfast - Research Portal:**  
[Link to publication record in Queen's University Belfast Research Portal](#)

**Publisher rights**  
Copyright 2018 Wiley. This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

**General rights**  
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**  
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

## Title:

Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: an analysis of two independent population-based databases

## Short title:

Lower oesophageal sphincter relaxation and cancer risk

## Authors:

Andrew D Spence MRCP MSc<sup>1</sup>, John Busby PhD<sup>1</sup>, Peter Murchie FRCGP PhD<sup>2</sup>, Andrew T Kunzmann PhD<sup>1</sup>, Úna C McMenamin PhD<sup>1</sup>, Helen G Coleman PhD<sup>1</sup>, Brian T Johnston FRCP MD<sup>3</sup>, Michael A O'Rourke PhD<sup>1</sup>, Liam J Murray MRCGP MD<sup>1</sup>, Lisa Iversen PhD<sup>2</sup>, Amanda J Lee PhD<sup>4</sup>, Chris R Cardwell PhD<sup>1</sup>

## Authors' affiliations:

<sup>1</sup>Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom

<sup>2</sup>Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom

<sup>3</sup>Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom

<sup>4</sup>Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom

## Corresponding author:

Dr Andrew Spence

Institute of Clinical Sciences Block B, Queen's University Belfast, Royal Victoria Hospital, Belfast, Northern Ireland, BT12 6BA.

Phone: +44 (0) 28 9063 5009

Fax: +44 (0) 28 90235900

Email: [aspence04@qub.ac.uk](mailto:aspence04@qub.ac.uk)

Keywords: Oesophageal cancer; Benzodiazepines; Calcium channel blockers; Nitrates;  $\beta$ 2 agonists

Article category:

Cancer Epidemiology

Novelty and impact:

Medications that decrease lower oesophageal sphincter pressure (benzodiazepines, calcium channel blockers, nitrates, xanthines and  $\beta$ 2 agonists) increase acid reflux, an oesophageal adenocarcinoma risk factor. Previous studies of associations between these medications and cancer risk have reached inconsistent conclusions, potentially reflecting limited power. We conducted the largest study yet using two independent datasets. Medications that decrease sphincter pressure were not associated with increased oesophageal cancer, apart from  $\beta$ 2 agonists. The  $\beta$ 2 agonist association merits further investigation.

Word count: Abstract – 213

Main text – 3,190

## ABSTRACT

Excessive lower oesophageal sphincter relaxation increases gastro-oesophageal acid reflux, an oesophageal adenocarcinoma risk factor. Medications that relax this sphincter (benzodiazepines, calcium channel blockers, nitrates,  $\beta$ 2 agonists and xanthines) could promote cancer. These medications were investigated in two independent datasets. In the Scottish Primary Care Clinical Informatics Unit (PCCIU) database, a nested case-control study of oesophageal cancer was performed using GP prescription records. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs) for medication use and oesophageal cancer. In UK Biobank, a cohort study was conducted using self-reported medication use. Cox regression was used to calculate hazard ratios (HRs) and 95% CIs for medication use and oesophageal cancer, and by tumour subtype. Overall, 1,979 oesophageal cancer patients were matched to 9,543 controls in PCCIU, and 355 of 475,768 participants developed oesophageal cancer in UK Biobank. None of the medications investigated were significantly associated with oesophageal cancer risk apart from  $\beta$ 2 agonists, which were associated with increased oesophageal cancer risk in PCCIU (adjusted OR 1.38, 95% CI 1.12, 1.70) but not in UK Biobank (adjusted HR 1.21, 95% CI 0.70, 2.08). Medications that relax the lower oesophageal sphincter were not associated with oesophageal cancer, apart from  $\beta$ 2 agonists. This increased cancer risk in  $\beta$ 2 agonist users merits further investigation.

## INTRODUCTION

Oesophageal cancer is the eighth most common cancer worldwide, accounting for 400,000 deaths each year.<sup>1</sup> Over recent decades survival from oesophageal cancer has remained poor (12% 5-year survival rate in Europe).<sup>2</sup>

Prolonged relaxation of the lower oesophageal sphincter results in increased gastro-oesophageal reflux,<sup>3</sup> a known risk factor for oesophageal adenocarcinoma.<sup>4</sup> Although the relationship between lower oesophageal sphincter tone and squamous cell carcinoma is less clearly established, non-acid gastro-oesophageal reflux has been associated with this cancer subtype.<sup>5,6</sup> Through smooth muscle relaxation mechanisms, several commonly used medications have been shown to relax the lower oesophageal sphincter, including benzodiazepines, calcium channel blockers, nitrates,  $\beta$ 2 agonists and xanthines,<sup>7-12</sup> with the greatest reduction in pressure being caused by  $\beta$ 2 agonists (30%).<sup>10</sup> Millions of these medications are prescribed each year for conditions such as anxiety, hypertension, angina and asthma, respectively.<sup>13,14</sup>

However, few epidemiological studies have explored the relationship between these medications and oesophageal cancer. Where studied, statistical power has been limited, as shown in a recent meta-analysis of these medications and oesophageal cancer risk, which included benzodiazepines (total of 406 cases), calcium channel blockers (total of 875 cases), nitrates (total of 980 cases),  $\beta$ 2 agonists (total of 1,291 cases) and xanthines (total of 984 cases).<sup>15-19</sup> Additionally, three of these studies relied upon self-reported medication use, and are therefore prone to recall bias.<sup>16,17,19</sup> Furthermore, these studies have observed inconsistent results for some medications,

for example xanthines (specifically, theophylline).<sup>17–19</sup> Given the widespread use of these medications it is a priority to establish if they increase oesophageal cancer risk.

We conducted two large independent population-based studies from Scotland and England to explore the association between medications that reduce lower oesophageal sphincter tone and the risk of developing oesophageal cancer.

## METHODS

### PCCIU: Data source

The Primary Care Clinical Informatics Unit Research (PCCIU) database contains computerised GP records including clinical diagnoses and prescriptions for approximately 15% of Scotland.<sup>20</sup> The PCCIU contains over two million patients registered at 393 Scottish GPs. Access to the PCCIU data was approved by the Research Applications and Data Management Team, University of Aberdeen. Ethical approval for the PCCIU analysis was obtained from the School of Medicine, Dentistry and Biomedical Sciences Research Ethics Committee at Queen's University Belfast (reference number: 15.43).

### PCCIU: Study design

A nested case-control study was conducted with cases defined as patients with a first ever diagnosis of oesophageal cancer (Read code category: B10) between January 1999 and April 2011. Up to five controls were randomly selected for each case matched on age, gender, year of diagnosis and general practice (GP). The index date for the cases was defined as the date of diagnosis of oesophageal cancer. The index date for the controls was the diagnosis date of their matched case. The start of the exposure period was the latest of 1st January 1996 (as prescriptions prior to this were less likely to have been electronically recorded) or the date of patient registration at a GP practice. Additionally, the start of the exposure period was truncated to the latest start date within each matched set of a case and controls to ensure all members of the matched set had an identical length of exposure period, removing the risk of time-window bias.<sup>21</sup> Cases and controls with a previous cancer diagnosis (other than non-

melanoma skin cancer), and those with less than three years of prescription records prior to index date, were excluded. The end of the exposure period was one year prior to the index date to avoid reverse causation due to increased exposure to healthcare professionals following symptoms of cancer.

#### PCCIU: Exposure data

The medication groups of interest were those that relax the lower oesophageal sphincter: benzodiazepines, calcium channel blockers, nitrates,  $\beta$ 2 agonists and xanthines. Supplementary Table 1 contains a list of medications included which were identified from the British National Formulary (71<sup>st</sup> edition).<sup>13</sup> Medication use was determined from GP prescription records).

#### PCCIU: Confounders

Confounders were identified from GP records in the exposure period defined above. Based on the Charlson index,<sup>22</sup> twelve comorbidities were identified using GP diagnosis codes (including acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease [COPD], connective tissue disease, peptic ulcer disease, diabetes mellitus, rheumatoid arthritis, chronic kidney disease and liver disease). Lifestyle risk factors for oesophageal cancer including smoking (never smoker, ex-smoker or current smoker), alcohol consumption (none, low [e.g., moderate or light drinker], or high intake [e.g., above recommended limits, chronic alcoholism]) and obesity (obese [BMI>30] or not obese) were extracted from GP records. Postcode of the GP practice was used to assign deprivation fifths using the Scottish Index of Multiple Deprivation.<sup>23</sup> Aspirin and statin use within the exposure period was identified, as



inverse associations have been shown with oesophageal cancer.<sup>24,25</sup>

#### PCCIU: Statistical analysis

We calculated descriptive statistics, comparing the demographics and clinical characteristics of cases and controls. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (95% CI) for the association between medication use (in the exposure period) and risk of oesophageal cancer. In the main analysis, the matched design accounted for age, gender, general practice and year of diagnosis, with additional adjustments made for comorbidities (as described), and aspirin and statin use. As the patients were matched on general practice, they were inherently matched on deprivation level, as the available deprivation measure was based upon the address of their GP practice. In the main analysis for respiratory-based medications studied ( $\beta_2$  agonists and xanthines) additional adjustment for steroid-based inhaler medication were conducted, but a sensitivity analysis was also added not adjusting for these medications to avoid the potential for over-adjustment. Analyses were repeated by number of prescriptions and by medication (restricted to medications prescribed to at least 1% of the patients in the analysis) (Supplementary Table 1).

A sensitivity analysis was conducted additionally adjusting for lifestyle factors (smoking, alcohol and obesity) using both a complete case approach and multiple imputation. The imputation used ordered logit models with age, gender and deprivation, separately for cases and controls. Multiple imputation with chained equations is a simulation-based approach for handling missing data which can lead to valid statistical inferences.<sup>26</sup> Sensitivity analyses were also conducted investigating

the impact of excluding prescriptions in the two years prior to the index date and defining medication users as patients with at least three prescriptions. Finally, we repeated the analysis combining gastric cancer (based upon Read code category B11) and oesophageal cancers as GPs could have misclassified junctional oesophageal carcinomas as gastric cancer.<sup>27</sup>

#### UK Biobank: Data source

The UK Biobank contains approximately 500,000 individuals aged between 40 and 69 from England, Scotland and Wales recruited between 2006 and 2010. The UK Biobank is linked to cancer registry data from the Health and Social Care Information Centre (in England and Wales) and the Scottish Cancer Registry (in Scotland).<sup>28</sup> The UK Biobank was approved by the North West Multi-Centre Research Ethics Committee, and all participants provided written informed consent.

#### UK Biobank: Study design

A prospective cohort study was conducted. Cases of oesophageal cancer were identified from cancer-registry records (ICD code C15) up to 2014. Patients with a previous cancer diagnosis, apart from non-melanoma skin cancer, were excluded. Patients were followed from 1 year after baseline (removing cancers that may have been present at baseline) until the date of cancer or censoring on the earlier of death, emigration or 30<sup>th</sup> June 2014 (the date at which cancer registry data was complete).

#### UK Biobank: Exposure data

Self-reported use of medications outlined previously was determined at the baseline electronic touchscreen data entry system or interview.

### UK Biobank: Confounders

All confounders were determined from the baseline visit. The twelve comorbidities previously mentioned were identified from patient interview/touch screen at baseline. In addition, other recognised risk factors retrieved from the UK Biobank database were hypertension, Alzheimer's disease, fruit and vegetable intake and educational degree. Lifestyle risk factors including smoking (never, former or current) and alcohol consumption (none, moderate [ $\leq 14$  units per week], heavy [ $> 14$  units per week]) were determined from the electronic touchscreen data entry system, at baseline. BMI was calculated from height and weight measurements recorded at baseline by trained research staff, and categorised (underweight [ $< 18.5$ ], normal weight [ $18.5-24.99$ ], overweight [ $25-29.99$ ], obese [ $> 30$ ]). The Townsend score based upon postcode of residence was determined as a measure of deprivation.<sup>29</sup> Self-reported aspirin and statin use were also identified.

### UK Biobank: Statistical analysis

The UK Biobank cohort was analysed using Cox regression with age as the underlying time scale (individuals were considered at risk from birth and under observation from age at baseline, left truncated) to calculate hazard ratios (HR) and 95% CIs for the association between medication use and oesophageal cancer. An initial adjusted analysis was conducted including gender, comorbidities, deprivation level, statin and aspirin use, for comparison with PCCIU estimates (not shown). The UK Biobank analysis contained further adjustment of other factors known to increase cancer risk which were not available in the PCCIU dataset, including lifestyle factors (including smoking, alcohol consumption and obesity), hypertension, Alzheimer's

disease, fruit and vegetable intake and educational degree. These adjustments made little difference to the estimates and only these estimates are shown. Similar to the PCCIU analysis, additional adjustment for steroid-based inhaler medication was included for patients using respiratory-based medications ( $\beta$ 2 agonists and xanthines). Sensitivity analysis was conducted by histological subtype (adenocarcinoma or squamous cell carcinoma). A sensitivity analysis was conducted starting follow-up at 2 years after diagnosis. Sensitivity analyses were conducted for  $\beta$ 2 agonists stratifying by asthma in order to reduce the risk of confounding by indication, and after adjustment for asthma. Finally, for comparison with  $\beta$ 2 agonist association, a separate analysis of inhaled steroid medication was conducted (as these are used to treat asthma and COPD, but are not known to relax the lower oesophageal sphincter). Analysis was performed using STATA 14 (StataCorp LP, College Station, TX, USA).

## RESULTS

### PCCIU

In PCCIU there were 1,979 oesophageal cancer cases and 9,543 control patients (Table 1). The median exposure time was 5.5 years (range 3.0-15.1 years).

Oesophageal cancer cases were more likely to smoke, have higher alcohol intake and be diagnosed with COPD and peptic ulcer disease.

Overall, a greater proportion of oesophageal cancer cases compared with controls used lower oesophageal sphincter relaxing medications (45.2% versus 39.1%). After adjustment for confounding, these medications were associated with a 23% increase in oesophageal cancer risk (adjusted OR 1.23 95% CI 1.10, 1.38) (Table 2). This association did not follow an exposure response as the adjusted OR for 1 to 12 prescriptions was 1.30 (95% CI 1.13, 1.48), whilst the adjusted OR for >12 prescriptions was 1.17 (95% CI 1.02, 1.35).

This association was largely driven by  $\beta$ 2 agonists, which were associated with a 38% increase in oesophageal cancer risk (adjusted OR 1.38, 95% CI 1.12, 1.70). The adjusted OR for 1 to 12 prescriptions was 1.42 (95% CI 1.14, 1.77) but the adjusted OR for greater use was 1.26 (95% CI 0.94, 1.69). Further analysis of specific respiratory-based medications showed only those containing salbutamol were significantly associated with oesophageal cancer (adjusted OR 1.26, 95% CI 1.03, 1.54) (Supplementary Table 2). There was little evidence of an association between oesophageal cancer risk and the other medications that reduce lower oesophageal sphincter pressure, specifically benzodiazepines (adjusted OR 0.94, 95% CI 0.79,

1.11), calcium channel blockers (adjusted OR 1.05, 95% CI 0.92, 1.20), nitrates (adjusted OR 1.09, 95% CI 0.92, 1.29) and xanthines (adjusted OR 1.40, 95% CI 0.88, 2.22) (Table 2).

In sensitivity analyses, the associations were generally similar when the 2 years prior to diagnosis were removed, when a minimum of 3 prescriptions were investigated and when adjustments for lifestyle factors were included, using either complete case or multiple imputation (Table 3). Analysis excluding the additional adjustment for steroid-based inhaler medication conducted for respiratory-based medications ( $\beta$ 2 agonists and xanthines) had minimal effect on results, with  $\beta$ 2 agonist medication remaining statistically significantly associated with oesophageal cancer (adjusted HR 1.27, 95% CI 1.08, 1.48). Associations were also similar for combined gastric or oesophageal cancer (Supplementary Table 3).

#### UK Biobank

The UK Biobank cohort contained 475,768 participants of which 355 were diagnosed with oesophageal cancer (Table 1). The median follow-up time was 5.6 years (range 1.0-8.6 years). In UK Biobank those with oesophageal cancer were more likely to be male, older, smoke, have higher alcohol intake, have higher BMI, and have COPD, amongst other comorbidities.

Overall, in comparison to those without oesophageal cancer a greater proportion of people who developed oesophageal cancer used one or more lower oesophageal sphincter relaxing medication (23.1% versus 14.1%). After adjustment for confounders, there was no evidence of an association between use of one or more

medication which lower oesophageal sphincter pressure and oesophageal cancer (adjusted HR 1.29, 95% CI 0.97, 1.71) (Table 4). Further, there was also no evidence of association for specific medication classes and oesophageal cancer:

benzodiazepines (adjusted HR 1.47, 95% CI 0.54, 3.96), calcium channel blockers (adjusted HR 0.94, 95% CI 0.64, 1.36), nitrates (adjusted HR 0.85, 95% CI 0.40, 1.82),  $\beta_2$  agonists (adjusted HR 1.21, 95% CI 0.70, 2.08) and xanthines (adjusted HR 2.46, 95% CI 0.58, 10.32) (Table 4).

Analyses by histological subtype also showed medications that relax the lower oesophageal sphincter are not associated with risk of oesophageal adenocarcinoma or squamous cell carcinoma. Further analyses demonstrated that there was no association between  $\beta_2$  agonist use and oesophageal cancer in patients with or without asthma (adjusted HR 1.69, 95% CI 0.76, 3.78 and adjusted HR 0.57, 95% CI 0.17, 1.92, respectively) (Table 5). Similarly, after additional adjustment for asthma, there was no evidence of  $\beta_2$  agonist association with oesophageal cancer (adjusted HR 1.24, 95% CI 0.66, 2.34). However, there was an association between  $\beta_2$  agonist use and oesophageal cancer when adjustment for steroid-based inhalers was removed (adjusted HR 1.66, 95% CI 1.16, 2.37) (Table 5).

Users of steroid based inhalers, prescribed for asthma, had a significantly increased risk of oesophageal cancer (adjusted HR 1.94, 95% CI 1.32, 2.86). Analyses by drug type revealed in the UK Biobank no specific individual medication was associated with increased risk of developing oesophageal cancer (Supplementary Table 2).

## DISCUSSION

In these two large independent population-based studies, there was little evidence of an association between oesophageal cancer risk and benzodiazepines, calcium channel blockers, nitrates or xanthines, despite the known reduction in oesophageal sphincter pressure associated with these medications. In contrast,  $\beta$ 2 agonist use was associated with a 38% increased odds of oesophageal cancer in PCCIU but not in UK Biobank.

The lack of association between benzodiazepines, calcium channel blockers and nitrates (all known to lower oesophageal sphincter pressure) and oesophageal cancer is similar to the results collated in a 2012 meta-analysis which was based upon fewer cases (406, 875 and 980 cases, respectively).<sup>30</sup> Our study includes over 2,300 cases allowing us to rule out relatively small potential increases in risk. Our study provides reassurance that these medications are safe with respect to oesophageal cancer risk.

The previous meta-analysis observed an increase in oesophageal adenocarcinoma risk with theophylline (xanthine) use (OR 1.55, 95% CI 1.05, 2.28).<sup>30</sup> Our study did not find a statistically significant increased risk in oesophageal cancer associated with xanthine use, however there was limited use of this drug in either population studied and when oesophageal and gastric cancer were combined in the PCCIU dataset an increased risk was observed for short term use (under 1 year), suggesting further studies containing larger numbers of xanthine users would be of value.



In the PCCIU data, we found  $\beta$ 2 agonists, such as salbutamol, were associated with increased risk of oesophageal cancer, results which are consistent with studies by Vaughn et al (OR 1.70, 95% CI 0.78, 3.71), Lagergren et al (OR 1.60, 95% CI 0.81, 3.15) and Ranka et al (OR 1.76, 95% CI 0.96, 3.23).<sup>16,17,19</sup> Our PCCIU findings are also similar to a recent cohort study of progression from Barrett's oesophagus to oesophageal cancer in which associations were observed with  $\beta$ 2 agonist (adjusted HR 1.27, 95% CI 0.68, 2.38) and steroid inhaler use (adjusted HR 2.11, 95% CI 1.12, 3.97), although that study contained a total of only 55 oesophageal cancer cases within their Barrett's oesophagus cohort.<sup>31</sup>

The cause of the increased risk of oesophageal cancer with  $\beta$ 2 agonist use in PCCIU is unknown. The lack of association in UK Biobank, the lack of dose response association, the association between other asthma medications (e.g. steroid-based) and oesophageal cancer risk provide evidence against a causal interpretation, particularly as several studies have shown marked increases in oesophageal cancer risk in asthma patients.<sup>32–34</sup> However,  $\beta$ 2 agonists have been shown to decrease oesophageal sphincter pressure thus potentially increasing the risk of gastro-oesophageal reflux disease,<sup>35</sup> providing a potential mechanism by which they could increase oesophageal cancer risk. Two previous studies have observed an increase in the premalignant Barrett's oesophagus risk in users of  $\beta$ 2 agonist<sup>36,37</sup> suggested this association could reflect reverse causality, where the symptoms of gastro-oesophageal reflux mimic asthma leading to the use of  $\beta$ 2 agonists.<sup>38,39</sup> Alternatively, the increased oesophageal cancer risk with  $\beta$ 2 agonist use could be real, particularly as studies have shown increased  $\beta$ 2 agonist receptor expression contributes to tumour growth via the cyclic-

AMP pathway in cancer cell lines, including the oesophageal squamous-cell carcinoma subtype.<sup>40,41</sup>

The main strengths of the current analyses were the size (2,334 oesophageal cancer cases) and the use of data from two independent studies. Also, we were able to adjust for a wide range of confounders, particularly in UK Biobank, to rule out confounding by comorbidity diagnoses and lifestyle factors. Furthermore in UK Biobank we were able to investigate by histological subtype. Unfortunately in PCCIU this was not possible and consequently the inclusion of squamous cell carcinoma cases in the PCCIU analysis could attenuate associations, if lower oesophageal sphincter relaxing medications only caused adenocarcinoma. However, this potential attenuation will be limited as based upon our UK Biobank data over seventy percent of oesophageal cancer cases are likely to be adenocarcinoma. In PCCIU there was possible misclassification of gastric cardia cancers, however as the risk estimates for combined gastric and oesophageal cancer were similar to the individual cancers the impact of this potential confounding factor is reduced (Supplementary Table 3). Another significant strength is that the prescription data in PCCIU is from GP prescribing records and thus recall bias is eliminated.

We also cannot rule out residual confounding by incompletely recorded confounders or unknown exposures associated with both lower oesophageal sphincter relaxing medication use and oesophageal cancer. We did not adjust for PPI use, Barrett's oesophagus or oesophagitis because, although possible, these covariates are likely to be on the causal pathway between the medications and oesophageal cancer. Finally, dose response analyses could only be performed in the PCCIU dataset and were

conducted by number of prescriptions, but as the length of prescriptions may vary this could result in some measurement error in analysis of longer-term use.

In conclusion, there was little evidence that benzodiazepines, nitrates, and calcium channel blockers increase oesophageal cancer risk providing reassurance that these widely used medications are not associated with oesophageal cancer. The increased risk of oesophageal cancer with  $\beta$ 2 agonist merits further investigation but as the association was limited to one dataset, and there was no exposure response relationship, a causal interpretation seems less likely.

#### Acknowledgements

We acknowledge collaboration with the Research Applications and Data Management Team lead by Ms Katie Wilde, University of Aberdeen in conducting this study. This research has been conducted using the UK Biobank Resource under application number 34374.

There are no financial interests by any authors.

There are no conflicts of interest.

#### Author contributions

The study was conceived and designed by CRC, PM, LI, and AL. PM, CRC, LI and AL obtained the data from the Primary Care Clinical Informatics Unit Research, Scotland whereas LJM, ÚCMcM, CRC, BTJ, HGC obtained the UK Biobank data. ADS, JB, ATK, UCMcM and CRC analysed the data. ADS, JB, MO'R, BTJ and

CRC interpreted the results and drafted the manuscript. All authors reviewed the final manuscript and agree to submission.

## REFERENCES

1. World Health Organisation. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide; 2012. Available at: [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx) [Accessed June 20, 2016].
2. Angelis R De, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EURO CARE-5-a population-based study. *Lancet Oncol* 2013;2045:1–12.
3. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. *N Engl J Med* 1982;307:1547–52.
4. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340:825–31.
5. Uno K, Iijima K, Hatta W, et al. Direct Measurement of Gastroesophageal Reflux Episodes in Patients With Squamous Cell Carcinoma by 24-h pH-Impedance Monitoring. *Am J Gastroenterol* 2011;106:1923–1929.
6. Kgomo M, Mokoena TR, Ker JA. Non-acid gastro-oesophageal reflux is associated with squamous cell carcinoma of the oesophagus. *BMJ Open Gastroenterol* 2017;4:e000180.
7. Stacher G, Schneider C, Steinringer H, et al. Effects of 3-days' intake of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate, on oesophageal motility. *Aliment Pharmacol Ther* 1997;11:967–71.
8. Wong R, Maydonovitch C, Garcia J, Johnson L CD. The Effect of Terbutaline Sulfate, Nitroglycerin, and Aminophylline on Lower Esophageal Sphincter Pressure and Radionuclide Esophageal Emptying in Patients with Achalasia.

- Gastroenterology 1987;9:386–389.
9. Gelfond M, Rozen P GT. Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. *Gastroenterology* 1982;83:963–969.
  10. DiMarino AJ, Cohen S. Effect of an oral beta2-adrenergic agonist on lower esophageal sphincter pressure in normals and in patients with achalasia. *Dig Dis Sci* 1982;27:1063–1066.
  11. Berquist WE, Rachelefsky GS, Kadden M, et al. Effect of theophylline on gastroesophageal reflux in normal adults. *J Allergy Clin Immunol* 1981;67:407–11.
  12. Rushnak MJ, Leevy CM. Effect of diazepam on the lower esophageal sphincter. A double-blind controlled study. *Am J Gastroenterol* 1980;73:127–30.
  13. British Medical Association and the Royal Pharmaceutical Society of Great Britain. *British National Formulary*. 68th ed.; 2014. Available at: <http://www.bnf.org/bnf/index.htm>.
  14. Powell-Smith A GB. OpenPrescribing. Available at: <https://openprescribing.net/> [Accessed April 3, 2017].
  15. Alexandre L, Broughton T, Loke Y, et al. Meta-analysis: risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter. *Dis Esophagus* 2012;25:535–544.
  16. Ranka S, Gee JM, Johnson IT, et al. Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer. A case-control study. *Digestion* 2006;74:109–15.
  17. Lagergren J, Bergstrom R, Adami HO et al. Association between Medications

- That Relax the Lower Esophageal Sphincter and Risk for Esophageal Adenocarcinoma. *Ann Intern Med* 2000;133:165–175.
18. Fortuny J, Johnson CC, Bohlke K, et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. *Clin Gastroenterol Hepatol* 2007;5:1154–1159.
  19. Vaughan L, Farrow C, Hansten D, et al. Risk of Esophageal and Gastric Adenocarcinomas in Relation to Use of Calcium Channel Blockers, Asthma Drugs, and Other Medications that Promote Gastroesophageal Reflux. *Cancer Epidemiol Biomarkers Prev* 1998;7:749–756.
  20. The Institute of Applied Health Sciences. Primary Care Clinical Informatics Unit. Available at: <http://www.abdn.ac.uk/iahs/research/primary-care/pcciu/index.php> [Accessed October 20, 2016].
  21. Suissa S, Anello SD, Vahey S, et al. Time-Window Bias in Case-Control Studies : Statins and Lung Cancer. *Epidemiology* 2011;22:228–231.
  22. Charlson M, Szatrowki TP, Peterson J GJ. Validation of a combined comorbidity index. *J Clin Epidemiol* 1994;47:1245–51.
  23. Donnelly R. *Scottish Index of Multiple Deprivation 2009: General Report. Edinburgh, UK: Office of the Chief Statistician (The Scottish Government) (2009). 2009.*
  24. Chan KKW, Oza AM, Siu LL. The Statins as Anticancer Agents. *Clin Cancer Res* 2003;9:10–19.
  25. Macfarlane T V, Lefevre K, Watson MC. Aspirin and non-steroidal anti-inflammatory drug use and the risk of upper aerodigestive tract cancer. *Br J Cancer* 2014;111:1852–9.
  26. White IR, Royston P, Wood AM. Multiple imputation using chained equations:

- Issues and guidance for practice. *Stat Med* 2011;30:377–399.
27. Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several? *Semin Oncol* 2004;31:444–9.
  28. UK Biobank. Cancer data: linkage from national cancer registries. 2013. Available at: <http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=115558> [Accessed February 4, 2017].
  29. Townsend P, Phillimore P, Beattie A. *Health and deprivation : inequality and the North*. London, UK: Croom Helm; 1988.
  30. Alexandre L, Broughton T, Loke Y, et al. Meta-analysis: Risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter. *Dis Esophagus* 2012;25:535–544.
  31. Cooper S, Menon S, Nightingale P, et al. Risk factors for the development of oesophageal adenocarcinoma in Barrett’s oesophagus: a UK primary care retrospective nested case-control study. *United Eur Gastroenterol J* 2014;2:91–8.
  32. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients hospitalized for asthma. *Br J Cancer* 2001;85:1317–21.
  33. Ji J, Shu X, Li X, et al. Cancer risk in hospitalised asthma patients. *Br J Cancer* 2009;100:829–833.
  34. Liu X, Hemminki K, Försti A, et al. Cancer risk and mortality in asthma patients: A Swedish national cohort study. *Acta Oncol (Madr)* 2015;54:1120–1127.
  35. Lacy BE, Mathis C, DesBiens J, et al. The effects of nebulized albuterol on esophageal function in asthmatic patients. *Dig Dis Sci* 2008;53:2627–33.



36. Corley DA, Levin TR, Habel LA, et al. Barrett's esophagus and medications that relax the lower esophageal sphincter. *Am J Gastroenterol* 2006;101:937–944.
37. Ladanchuk TC, Johnston BT, Murray LJ, et al. Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications. *Scand J Gastroenterol* 2010;45:1397–1403.
38. Havemann BD, Henderson CA, El-Serag HB, et al. The association between gastro-oesophageal reflux disease and asthma: a systematic review. *Gut* 2007;56:1654–1664.
39. Kiljander TO, Salomaa E-RM, Hietanen EK, et al. Gastroesophageal Reflux in Asthmatics. *Chest* 1999;116:1257–1264.
40. Quốc Lu'ong KV, Nguyễn LTH. The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. *Cancer Manag Res* 2012;4:431–45.
41. Liu X, Wu WKK, Yu L, et al. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via  $\beta$ -adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. *J Cell Biochem* 2008;105:53–60.

Table 1. Characteristics of Cases and Controls in the PCCIU and UK Biobank Databases

Characteristic	PCCIU		UK Biobank	
	EC cases [n=1,979]	Matched controls [n=9,543]	EC cases [n=355]	Non-EC cohort members [n=475,413]
Year of diagnosis				
1999 – 2003	665 (33.6%)			
2004 – 2007	910 (46.0%)		1 (0.3%)	
2008 – 2011	404 (20.4%)		102 (28.7%)	
2012 – 2015			252 (71.0%)	
Age at index date/baseline				
0-39	10 (0.5%)	52 (0.5%)		
40-59	414 (20.9%)	2070 (21.7%)	111 (31.3%)	274,848 (57.9%)
60-79	1207 (61.0%)	5897 (61.8%)	244 (68.7%)	200,565 (42.1%)
80+	348 (17.6%)	1524 (16.0%)		
Mean (SD)	68.3 (11.1)	68.8 (11.3)	61.9 (5.8)	56.3 (8.1)
Male	1364 (68.9%)	6568 (68.8%)	266 (74.9%)	219,160 (46.2%)
Alcohol consumption				
None	314 (21.7%)	1430 (22.2%)	39 (11.0%)	38,178 (8.0%)
Low	1005 (69.5%)	4638 (72.1%)	155 (43.7%)	257,159 (54.2%)
High	127 (8.8%)	363 (5.6%)	154 (43.4%)	168,505 (35.5%)
Missing/did not answer	533	3112	7	11,571
Smoking				
Never	544 (32.2%)	3232 (43.8%)	109 (30.7%)	260,747 (54.9%)
Ex-smoker	578 (34.3%)	2383 (32.3%)	168 (47.3%)	162,538 (34.2%)
Current smoker	562 (33.4%)	1756 (23.8%)	77 (21.7%)	50,572 (10.7%)
Missing	295	2172	1	1,910
Obesity				
Underweight <sup>§</sup>			3 (0.9%)	2,441 (0.5%)
Normal weight <sup>§</sup>			67 (19.1%)	153,697 (32.5%)
Overweight <sup>§</sup>			162 (46.2%)	200,896 (42.5%)
Obese	276 (13.9%)	1945 (20.4%)	119 (33.9%)	115,436 (24.4%)
Missing/not obese	1703 (86.1%)	7598 (79.6%)		
Missing			4	2,947
Deprivation (fifths)				
1 (least deprived)	242 (12.4%)	1141 (12.1%)	68 (19.2%)	95,083 (20.0%)
2	373 (19.1%)	1791 (19.0%)	61 (17.2%)	94,508 (19.9%)
3	406 (20.8%)	1970 (20.9%)	62 (17.5%)	94,852 (20.0%)
4	464 (23.8%)	2259 (24.0%)	72 (20.3%)	95,100 (20.0%)
5 (most deprived)	466 (23.9%)	2249 (23.9%)	92 (25.9%)	95,271 (20.1%)
Missing	28	133	0	599
Selected comorbidities				
Peptic ulcer disease	289 (14.6%)	880 (9.2%)	11 (3.1%)	5,000 (1.1%)
COPD	234 (11.8%)	787 (8.2%)	10 (2.8%)	7,529 (1.6%)
Diabetes mellitus	197 (10.0%)	922 (9.7%)	36 (10.1%)	23,868 (5.0%)
Acute myocardial infarction	169 (8.5%)	744 (7.8%)	18 (5.1%)	10,812 (2.3%)
Cerebrovascular disease	166 (8.4%)	750 (7.9%)	11 (3.1%)	6,327 (1.3%)

COPD = Chronic obstructive pulmonary disease

EC = Oesophageal cancer

<sup>§</sup>Data not available in PCCIU dataset

Comorbidity diagnosed from before the start of follow up to one year prior to end of follow up

Table 2. Association Between Medications That Relax the Lower Oesophageal Sphincter and Risk of Oesophageal Cancer in PCCIU Case-Control Data.

Medication	Cases	Controls	Unadjusted OR (95% CI)	Adjusted OR <sup>a</sup> (95% CI)	P-value
	n=1,979	n=9,543	n=11,522	n=11,522	
Any LOS medication					
Never user	1,084 (54.8%)	5,816 (60.9%)	Ref	Ref	.
Ever user	895 (45.2%)	3,727 (39.1%)	1.31 (1.18,1.45)	1.23 (1.10,1.38)	<0.01
1-12 prescriptions	394 (19.9%)	1,591 (16.7%)	1.35 (1.18,1.53)	1.30 (1.13,1.48)	<0.01
>12 prescriptions	501 (25.3%)	2,136 (22.4%)	1.27 (1.13,1.44)	1.17 (1.02,1.35)	0.03
Benzodiazepines					
Never user	1,782 (90.0%)	8,577 (89.9%)	Ref	Ref	.
Ever user	197 (10.0%)	966 (10.1%)	0.98 (0.83,1.15)	0.94 (0.79,1.11)	0.46
1-12	141 (7.1%)	643 (6.7%)	1.07 (0.88,1.29)	1.03 (0.85,1.26)	0.75
>12	56 (2.8%)	323 (3.4%)	0.80 (0.60,1.08)	0.76 (0.56,1.02)	0.07
Calcium channel blockers					
Never user	1,556 (78.6%)	7,655 (80.2%)	Ref	Ref	.
Ever user	423 (21.4%)	1,888 (19.8%)	1.10 (0.97,1.25)	1.05 (0.92,1.20)	0.47
1-12	150 (7.6%)	712 (7.5%)	1.04 (0.86,1.25)	0.99 (0.81,1.20)	0.90
>12	273 (13.8%)	1,176 (12.3%)	1.15 (0.99,1.33)	1.09 (0.93,1.28)	0.28
Nitrates					
Never user	1,683 (85.0%)	8,298 (87.0%)	Ref	Ref	.
Ever user	296 (15.0%)	1,245 (13.0%)	1.17 (1.02,1.35)	1.09 (0.92,1.29)	0.31
1-12	182 (9.2%)	713 (7.5%)	1.25 (1.05,1.49)	1.19 (0.98,1.44)	0.08
>12	114 (5.8%)	532 (5.6%)	1.05 (0.85,1.30)	0.94 (0.74,1.20)	0.62
β <sub>2</sub> agonists					
Never user	1,655 (83.6%)	8,387 (87.9%)	Ref	Ref	.
Ever user <sup>b</sup>	324 (16.4%)	1,156 (12.1%)	1.43 (1.25,1.64)	1.38 (1.12,1.70)	<0.01
1-12 <sup>b</sup>	176 (8.9%)	603 (6.3%)	1.50 (1.25,1.79)	1.42 (1.14,1.77)	<0.01
>12 <sup>b</sup>	148 (7.5%)	553 (5.8%)	1.36 (1.12,1.64)	1.26 (0.94,1.69)	0.12
Xanthines					
Never user	1,951 (98.6%)	9,464 (99.2%)	Ref	Ref	.
Ever user <sup>b</sup>	28 (1.4%)	79 (0.8%)	1.76 (1.13,2.73)	1.40 (0.88,2.22)	0.16
1-12 <sup>b</sup>	16 (0.8%)	40 (0.4%)	2.01 (1.12,3.62)	1.64 (0.90,3.00)	0.11
>12 <sup>b</sup>	12 (0.6%)	39 (0.4%)	1.50 (0.78,2.88)	1.16 (0.59,2.28)	0.66

LOS = lower oesophageal sphincter

<sup>a</sup>Calculated using conditional logistic regression, with age, gender, location of residence (deprivation level) and year of diagnosis were accounted for by matched design, and adjustment for acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, rheumatoid arthritis, chronic kidney disease, liver disease, statins, and aspirin

<sup>b</sup>Additional adjustment for steroid-based inhalers

Table 3. Sensitivity Analysis for the Association Between Medications That Relax the Lower Oesophageal Sphincter and Risk of Oesophageal Cancer in the PCCIU

Medication	Cases	Controls	Unadjusted OR (95% CI)	Adjusted OR <sup>a</sup> (95% CI)	P-value
Any LOS medication					
Exposure lag (excl 2 years) <sup>b</sup>	781 (39.5%)	3,287 (34.4%)	1.25 (1.13,1.39)	1.17 (1.04,1.32)	<0.01
Ever use ≥3 <sup>c</sup>	718 (36.3%)	3,057 (32.0%)	1.21 (1.09,1.35)	1.11 (0.99,1.25)	0.08
Lifestyle adjusted <sup>d</sup>	710 (50.0%)	2,738 (44.4%)	1.30 (1.14,1.47)	1.22 (1.06,1.41)	<0.01
Lifestyle adjusted (MI) <sup>d</sup>	895 (45.2%)	3,727 (39.1%)	1.31 (1.18,1.45)	1.24 (1.10,1.39)	<0.01
Benzodiazepines					
Exposure lag (excl 2 years) <sup>b</sup>	162 (8.2%)	797 (8.4%)	0.97 (0.81,1.16)	0.94 (0.79,1.13)	0.53
Ever use ≥3 <sup>c</sup>	98 (5.0%)	516 (5.4%)	0.89 (0.71,1.12)	0.85 (0.67,1.06)	0.15
Lifestyle adjusted <sup>d</sup>	156 (11.0%)	697 (11.3%)	1.00 (0.82,1.22)	0.87 (0.71,1.07)	0.18
Lifestyle adjusted (MI) <sup>d</sup>	197 (10.0%)	966 (10.1%)	0.98 (0.83,1.15)	0.87 (0.73,1.03)	0.10
Calcium channel blockers					
Exposure lag (excl 2 years) <sup>b</sup>	366 (18.5%)	1,627 (17.0%)	1.11 (0.97,1.26)	1.05 (0.91,1.21)	0.49
Ever use ≥3 <sup>c</sup>	387 (19.6%)	1,684 (17.6%)	1.14 (1.00,1.30)	1.09 (0.95,1.25)	0.20
Lifestyle adjusted <sup>d</sup>	348 (24.5%)	1,451 (23.5%)	1.09 (0.94,1.26)	1.08 (0.92,1.27)	0.33
Lifestyle adjusted (MI) <sup>d</sup>	423 (21.4%)	1,888 (19.8%)	1.10 (0.97,1.25)	1.10 (0.96,1.26)	0.16
Nitrates					
Exposure lag (excl 2 years) <sup>b</sup>	247 (12.5%)	1,095 (11.5%)	1.10 (0.94,1.28)	1.00 (0.84,1.19)	0.99
Ever use ≥3 <sup>c</sup>	212 (10.7%)	942 (9.9%)	1.08 (0.92,1.27)	0.96 (0.79,1.16)	0.65
Lifestyle adjusted <sup>d</sup>	243 (17.1%)	936 (15.2%)	1.15 (0.97,1.37)	1.09 (0.88,1.34)	0.42
Lifestyle adjusted (MI) <sup>d</sup>	296 (15.0%)	1,245 (13.0%)	1.17 (1.02,1.35)	1.11 (0.94,1.32)	0.23
β2 agonists					
Exposure lag (excl 2 years) <sup>b,e</sup>	280 (14.1%)	999 (10.5%)	1.41 (1.22,1.63)	1.33 (1.07,1.66)	0.01
Ever use ≥3 <sup>c,e</sup>	247 (12.5%)	893 (9.4%)	1.38 (1.19,1.60)	1.23 (0.97,1.57)	0.09
Lifestyle adjusted <sup>d,e</sup>	257 (18.1%)	836 (13.6%)	1.39 (1.18,1.64)	1.25 (0.97,1.61)	0.09
Lifestyle adjusted (MI) <sup>d,e</sup>	324 (16.4%)	1,156 (12.1%)	1.43 (1.25,1.64)	1.38 (1.12,1.70)	<0.01
Not Adjusting for steroid-based inhalers	324 (16.4%)	1,156 (12.1%)	1.43 (1.25,1.64)	1.27 (1.08,1.48)	<0.01
Xanthines					
Exposure lag (excl 2 years) <sup>b,e</sup>	23 (1.2%)	68 (0.7%)	1.67 (1.03,2.70)	1.32 (0.80,2.18)	0.28
Ever use ≥3 <sup>c,e</sup>	18 (0.9%)	54 (0.6%)	1.63 (0.95,2.80)	1.26 (0.71,2.21)	0.43
Lifestyle adjusted <sup>d,e</sup>	23 (1.6%)	55 (0.9%)	1.72 (1.01,2.93)	1.36 (0.77,2.41)	0.29
Lifestyle adjusted (MI) <sup>d,e</sup>	28 (1.4%)	79 (0.8%)	1.76 (1.13,2.73)	1.40 (0.88,2.22)	0.16
Not Adjusting for steroid-	28 (1.4%)	79 (0.8%)	1.76 (1.13,2.73)	1.44 (0.91,2.28)	0.12

based inhalers

---

\*per 1000 person years

LOS = lower oesophageal sphincter

<sup>a</sup>Calculated using conditional logistic regression, with age, gender, location of residence (deprivation level) and year of diagnosis were accounted for by matched design, and adjustment for acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus,, rheumatoid arthritis, chronic kidney disease, liver disease, statins and aspirin

<sup>b</sup>Analysis excludes patients who died within 2 years of oesophageal cancer diagnosis

<sup>c</sup>Analysis restricted for those patients who received a minimum of 3 prescriptions of these medications

<sup>d</sup>Additional adjustment for lifestyle factors: obesity, alcohol intake and positive smoking history

<sup>e</sup>Additional adjustment for steroid-based inhalers

Table 4. Association Between Medications That Relax the Lower Oesophageal Sphincter and Risk of Oesophageal Cancer in UK Biobank Cohort by Subtype.

Medication	Users Cases (person-years <sup>*</sup> )	Non-users Cases (person-years <sup>*</sup> )	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	p
Any oesophageal cancer			n=355	n=323	
Any LOS relaxing medication	82 (299.5)	273 (1859.1)	1.48 (1.15,1.89)	1.29 (0.97,1.71)	0.08
Benzodiazepines	4 (12.4)	351 (2142.5)	1.68 (0.63,4.50)	1.47 (0.54,3.96)	0.44
Calcium channel blockers	39 (143.0)	316 (2011.9)	1.21 (0.86,1.69)	0.94 (0.64,1.36)	0.92
Nitrates	8 (26.7)	347 (2128.2)	1.22 (0.61,2.47)	0.85 (0.40,1.82)	0.69
β2 agonists <sup>b</sup>	41 (148.6)	314 (2006.3)	1.67 (1.21,2.31)	1.21 (0.70,2.08)	0.49
Xanthines <sup>b</sup>	2 (2.6)	324 (2152.3)	3.74 (0.93,15.00)	2.46 (0.58,10.32)	0.22
Oesophageal adenocarcinoma			n=258	n=232	
Any LOS relaxing medication	58 (299.5)	200 (1859.1)	1.41 (1.05,1.90)	1.18 (0.84,1.65)	0.33
Benzodiazepines	3 (12.4)	255 (2142.5)	1.73 (0.55,5.39)	1.70 (0.54,5.37)	0.36
Calcium channel blockers	27 (143.0)	231 (2011.9)	1.13 (0.76,1.69)	0.86 (0.52,1.26)	0.50
Nitrates	7 (26.7)	251 (2128.2)	1.47 (0.69,3.11)	1.05 (0.46,2.40)	0.90
β2 agonists <sup>b</sup>	29 (148.6)	229 (2006.3)	1.62 (1.10,2.38)	1.27 (0.67,2.41)	0.47
Xanthines <sup>b</sup>	2 (2.6)	256 (2152.3)	5.12 (1.27,20.59)	3.78 (0.88,16.23)	0.07
Squamous cell carcinoma			n=75	n=70	
Any LOS relaxing medication	18 (299.5)	57 (1859.1)	1.59 (0.93,2.71)	1.66 (0.91,3.03)	0.10
Benzodiazepines	1 (12.4)	74 (2142.5)	2.01 (0.28,14.49)	1.26 (0.17,9.23)	0.82
Calcium channel blockers	7 (143.0)	68 (2011.9)	1.03 (0.47,2.27)	1.06 (0.44,2.54)	0.90
Nitrates	0	75 (2128.2)	-	-	-
β2 agonists <sup>b</sup>	12 (148.6)	63 (2006.3)	2.45 (1.32,4.54)	1.79 (0.65,4.97)	0.26
Xanthines <sup>b</sup>	0	75 (2152.3)	-	-	-

\*per 1000 person years

LOS = lower oesophageal sphincter

<sup>a</sup>Cox regression model adjusted for acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, rheumatoid arthritis, chronic kidney disease, hypertension, Alzheimer's disease, liver disease, peptic ulcer disease, sex, body mass index, fruit and vegetable intake, alcohol intake, smoking status, deprivation level, educational degree, statins, aspirin and age accounted for by using age as the underlying time scale in the Cox regression model

<sup>b</sup>Additionally adjusted for steroid-based inhalers

Table 5. Sensitivity Analysis for the Association Between Medications That Relax the Lower Oesophageal Sphincter and Risk of Oesophageal Cancer in the UK Biobank

Medication	Users [cases] (person years*)	Non-users [cases] (person years*)	Unadjusted HR (95% CI)	Adjusted HR <sup>a</sup> (95% CI)	p
Any LOS medication					
Exposure lag (excl 2 years) <sup>b</sup>	66 (233.5)	222 (1455.9)	1.48 (1.12,1.96)	1.10 (0.77,1.56)	0.61
Benzodiazepines					
Exposure lag (excl 2 years) <sup>b</sup>	1 (9.7)	287 (1676.2)	0.51 (0.07,3.66)	0.43 (0.06,3.11)	0.41
Calcium channel blockers					
Exposure lag (excl 2 years) <sup>b</sup>	32 (111.0)	256 (1574.8)	1.25 (0.86,1.81)	1.03 (0.68,1.55)	0.91
Nitrates					
Exposure lag (excl 2 years) <sup>b</sup>	7 (20.9)	281 (1665.0)	1.34 (0.63,2.84)	0.89 (0.39,2.01)	0.78
β2 agonists					
Exposure lag (excl 2 years) <sup>b,c</sup>	32 (116.2)	256 (1569.7)	1.60 (1.11,2.32)	1.12 (0.61,2.08)	0.71
In asthma patients <sup>e,c</sup>	35 (129.5)	13 (121.6)	2.34 (1.24,4.44)	1.69 (0.76,3.78)	0.20
In non-asthma patients <sup>f,i</sup>	6 (19.1)	301 (1884.7)	1.45 (0.64,3.25)	0.57 (0.17,1.92)	0.37
Additionally adjusted for asthma <sup>g,i</sup>	41 (148.6)	314 (2006.3)	1.67 (1.21,2.31)	1.24 (0.66,2.34)	0.51
Without adjusting for steroid-based inhalers <sup>d</sup>	41 (148.6)	314 (2006.3)	1.67 (1.21,2.31)	1.66 (1.16,2.37)	0.01
Xanthines					
Exposure lag (excl 2 years) <sup>b,c</sup>	2 (2.0)	286 (1683.9)	4.70 (1.17,18.90)	3.16 (0.74,13.44)	0.12
In asthma patients <sup>e,c</sup>	2 (2.2)	46 (249.0)	4.05 (0.98,16.72)	3.55 (0.83,15.25)	0.09
Without adjusting for steroid-based inhalers <sup>d</sup>	2 (2.6)	324 (2152.3)	3.74 (0.93,15.00)	3.58 (0.87,14.82)	0.08
Steroid-based inhalers					
Overall risk <sup>h</sup>	31 (92.8)	324 (2042.1)	1.86 (1.29,2.69)	1.94 (1.32,2.86)	<0.01
Adjusting for β2 agonists <sup>h</sup>	31 (92.8)	324 (2042.1)	1.86 (1.29,2.69)	1.65 (0.91,2.99)	0.10

\*per 1000 person years

LOS = lower oesophageal sphincter

<sup>a</sup>Cox regression model adjusted for acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, rheumatoid arthritis, chronic kidney disease, hypertension, Alzheimer's disease, liver disease, peptic ulcer disease, sex, body mass index, fruit and vegetable intake, alcohol intake, smoking status, deprivation level, educational degree, statins, aspirin and age accounted for by using age as the underlying time scale in the Cox regression model

<sup>b</sup>Analysis excluding patients who died within 2 years of oesophageal cancer diagnosis

<sup>c</sup>Additional adjustment for steroid-based inhalers

<sup>d</sup>Main analysis (excluding 1 year after diagnosis) without adjustment for steroid-based inhalers

<sup>e</sup>Main analysis (excluding 1 year after diagnosis) stratified by restricting to patients with a self reported asthma diagnosis

<sup>f</sup>Main analysis (excluding 1 year after diagnosis) stratified by restricting to patients without an asthma diagnosis

<sup>g</sup>Main analysis (excluding 1 year after diagnosis) with additional adjustment for asthma diagnosis

<sup>h</sup>Main analysis (excluding 1 year after diagnosis) for patients prescribed steroid-based inhalers

<sup>i</sup>Additional adjustment for β2 agonist prescriptions

Supplementary Table 1. Generic and propriety names for medications included in this study

Type of medication	Generic / propriety medication name
Aspirin	Asasantin, Aspirin, Caprin, Co-codaprin, Micropirin, Migramax, Nu-Seals
Benzodiazepine	Alprazolam, Ativan, Chlordiazepoxide, Dalmane, Dialar, Diazemuls, Diazepam, Diazepam Desitin, Diazepam Rectubes, Flurazepam, Librium, Loprazolam, Lorazepam, Mogadon, Nitrazepam, Oxazepam, Rimapam, Stesolid, Temazepam, Tensium, Xanax
Calcium channel blocker	Adalat, Adipine, Adizem, Amlodipine, Angitil, Beta-Adalat, Cardene, Cardioplen, Coracten, Cordilox, Dilcardia, Diltiazem, Dilzem, Exforge, Felodipine, Felogen, Felotens, Fortipine, Isradipine, Istin, Keloc, Lacidipine, Lercandipine, Motens, Neofel, Nicardipine, Nifedipine, Nifedipress, Nimodipine, Nimotop, Parmid, Plendil, Securon, Slozem, Tenif, Tensipine, Tildiem, Triapin, Univer, Valni, Vascalpha, Verapamil, Verapress, Vertab, Viazem, Zanidip, Zemtard, Zolvera
Nitrate	Angitak, Chemydur, Clytrin, Coro-nitro, Deponit, Elantan, GTN, Glyceryl trinitrate, Imdur, Isib, Ismo, Isodur, Isoket, Isosorbide dinitrate, Isosorbide mononitrate, Isotard, Minitran, Modisal, Monomax, Monomil, Monosorb, Nitro-Dur, Nitrocine, Nitrolingual, Nitromin, Nitronal, Percutol, Transderm-Nitro, Zemon
β2 agonist	Airomir, Airlsalb, Asmasal, Atimos, Bambec, Bambuterol, Bricanyl, Combivent, Duaklir, Easyhaler, Flutiform, Foradil, Formoterol, Fostair, Indacaterol, Ipramol, Neovent, Olodaterol, Onbrez Breezhaler, Oxis, Pulvinal, Salamol, Salapin, Salbulin, Salbutamol, Salipraneb, Salmeterol, Seretide, Serevent, Spiolto, Striverdi, Symbicort, Terbutaline, Ultibro Breezhaler, Ventmax, Ventolin
Statin	Atorvastatin, Cholib, Crestor, Dorisin, Fluvastatin, Inegy, Lescol, Lipitor, Lipostat, Luvinsta, Pinnactil, Pravastatin, Rosuvastatin, Simvador, Simvastatin, Steflavin, Zocor
Xanthine	Aminophylline, Nuelin, Phyllocontin, Slo-phyllin, Theophylline, Uniphyllin
Steroid inhalers	Asmabec, Asmanex, Bambec, Beclometasone, Beclomethasone, Budenofalk, Budesonide, Flixotide, Fluticasone, Pulmicort, Qvar, Seretide, Symbicort



Supplementary Table 2. Commonly prescribed medications within each substance (greater than 1% of total prescriptions) [PCCIU and UK Biobank databases]

## PCCIU

	Cases	Controls	Unadjusted OR (95% CI)	Adjusted OR <sup>o</sup> (95% CI)	p
Benzodiazepine					
Diazepam <sup>a</sup>	95 (4.8%)	549 (5.8%)	0.82 (0.66,1.03)	0.80 (0.64,1.01)	0.06
Temazepam <sup>b</sup>	62 (3.1%)	318 (3.3%)	0.93 (0.70,1.23)	0.91 (0.68,1.20)	0.50
Nitrazepam <sup>c</sup>	19 (1.0%)	117 (1.2%)	0.78 (0.48,1.28)	0.75 (0.46,1.24)	0.27
Calcium channel blockers					
Amlodipine <sup>d</sup>	215 (10.9%)	1,022 (10.7%)	1.01 (0.86,1.18)	0.96 (0.81,1.13)	0.63
Nifedipine <sup>e</sup>	101 (5.1%)	475 (5.0%)	1.02 (0.82,1.28)	1.00 (0.80,1.26)	0.97
Diltiazem <sup>f</sup>	82 (4.1%)	354 (3.7%)	1.13 (0.88,1.44)	1.01 (0.78,1.30)	0.96
Felodipine <sup>g</sup>	34 (1.7%)	153 (1.6%)	1.08 (0.73,1.59)	1.08 (0.73,1.60)	0.69
Verapamil <sup>h</sup>	17 (0.9%)	92 (1.0%)	0.89 (0.53,1.50)	0.81 (0.48,1.38)	0.44
Nitrates					
Glyceril Trinitrate <sup>i</sup>	273 (13.8%)	1,095 (11.5%)	1.23 (1.07,1.43)	1.17 (0.98,1.39)	0.08
Isosorbide Mononitrate <sup>j</sup>	144 (7.3%)	607 (6.4%)	1.14 (0.94,1.38)	1.03 (0.84,1.28)	0.76
β2 agonists <sup>q</sup>					
Salbutamol <sup>k</sup>	279 (14.1%)	1,007 (10.6%)	1.40 (1.21,1.62)	1.26 (1.03,1.54)	0.03
Salmeterol <sup>l</sup>	98 (5.0%)	335 (3.5%)	1.45 (1.15,1.83)	1.18 (0.88,1.59)	0.27
Terbutaline <sup>m</sup>	58 (2.9%)	192 (2.0%)	1.46 (1.08,1.98)	1.25 (0.90,1.75)	0.18
Formoterol <sup>n</sup>	26 (1.3%)	84 (0.9%)	1.50 (0.95,2.36)	1.15 (0.70,1.89)	0.57

## UK Biobank

	Users [cases] (person years)	Non-users [cases] (person years)	Unadjusted HR (95% CI)	Adjusted OR <sup>p</sup> (95% CI)	p
Benzodiazepine					
Diazepam <sup>a</sup>	3 (5716)	352 (2149181)	3.13 (1.01,9.76)	2.59 (0.83,8.13)	0.10
Calcium channel blockers					
Amlodipine <sup>d</sup>	23 (87968)	332 (2066929)	1.17 (0.76,1.78)	0.91 (0.57,1.43)	0.67
Nifedipine <sup>e</sup>	6 (12233)	349 (2142664)	2.13 (0.95,4.78)	1.96 (0.87,4.46)	0.11
Diltiazem <sup>f</sup>	3 (12898)	352 (2141999)	0.95 (0.31,2.97)	0.80 (0.25,2.52)	0.70
Felodipine <sup>g</sup>	4 (19447)	351 (2135450)	0.88 (0.33,2.36)	0.79 (0.29,2.14)	0.64
Verapamil <sup>h</sup>	2 (4475)	353 (2150422)	1.89 (0.47,7.61)	1.87 (0.46,7.53)	0.38
Nitrates					
Glyceril Trinitrate <sup>i</sup>	7 (20632)	348 (2134265)	1.40 (0.66,2.96)	1.00 (0.45,2.23)	0.99
Isosorbide Mononitrate <sup>j</sup>	5 (11957)	350 (2142939)	1.68 (0.69,4.06)	1.18 (0.47,2.98)	0.72
β2 agonists <sup>q</sup>					
Salbutamol <sup>k</sup>	31 (111919)	324 (2042978)	1.71 (1.18,2.47)	1.34 (0.84,2.15)	0.22
Salmeterol <sup>l</sup>	17 (39994)	338 (2114903)	2.29 (1.41,3.73)	1.59 (0.82,3.06)	0.17
Formoterol <sup>n</sup>	2 (15002)	353 (2139895)	0.72 (0.18,2.88)	0.42 (0.10,1.76)	0.23

<sup>a</sup>Diazepam: Dalar, Diazemuls, Diazepam, Diazepam Desitin, Diazepam Rectubes, Stesolid, Tensium;

<sup>b</sup>Temazepam: Temazepam; <sup>c</sup>Nitrazepam: Mogadon, Nitrazepam; <sup>d</sup>Amlodipine: Amlodipine, Exforge, Istin; <sup>e</sup>Nifedipine: Adalat, Beta-adalat, Coracten, Fortipine, Nifedipine, Nifedipress, Tenif, Valni;

<sup>f</sup>Diltiazem: Adizem, Angitil, Dildardia, Diltiazem, Dilzem, Slozem, Tildiem, Viazem, Zemtard;

<sup>g</sup>Felodipine: Cardioplen, Felodipine, Felogen, Felotens, Keloc, Neofel, Parmid, Plendil, Triapin,

Vasculpha; <sup>h</sup>Verapamil: Cordilox, Securon, Univer, Verapamil, Verapress, Vertab, Zolvera; <sup>i</sup>Glyceril

Trinitrate: Coro-nitro, Deponit, GTN, Glyceril trinitrate, Glytrin, Minitran, Nitrocline, Nitrolingual,

Nitromin, Nitronal, Percutol; <sup>j</sup>Isosorbide Mononitrate: Chemydur, Elantan, Imdur, Isib, Ismo, Isodur,

Isosorbide mononitrate, Isotard, Modisal, Monomax, Monomil, Monosorb, Zemon; <sup>k</sup>Salbutamol:

Airomir, Airsalb, Asmasal, Combivent, Salamol, Salapin, Salbulin, Salbutamol, Salipraneb, Ventmax,

Ventolin; <sup>l</sup>Salmeterol: Neevent, Salmeterol, Seretide, Serevent; <sup>m</sup>Terbutaline: Bricanyl, Terbutaline; <sup>n</sup>Formoterol: Atimos, Duaklir, Flutiform, Foradil, Formoterol, Fostair, Oxis, Symbicort

<sup>o</sup>Calculated using conditional logistic regression, with age, gender, location of residence (deprivation level) and year of diagnosis were accounted for by matched design, and adjustment for acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, chronic kidney disease, leukaemia, malignant lymphoma, liver disease, statins and aspirin

<sup>p</sup>Cox regression model additionally contains hypertension, diabetes, chronic obstructive pulmonary disease, congestive cardiac failure, acute myocardial infarction, Alzheimer's disease, renal failure, liver disease, peptic ulcer disease, peripheral vascular disease, sex, body mass index, fruit and vegetable intake, alcohol intake, smoking status, deprivation level, educational degree, statins, aspirin and age accounted for by using age as the underlying time scale in the Cox regression model

<sup>q</sup>Additional adjustment for steroid-based inhalers

Supplementary Table 3. Odds ratios (95% confidence interval) for risk of developing either gastric or oesophageal cancer for patients prescribed LOS relaxing medication (PCCIU database)

Medication	Cases	Controls	Unadjusted OR (95% CI)	Adjusted OR <sup>a</sup> (95% CI)	P-Value
	n	n			
Any LOS medication					
Never user	1,671 (53.9%)	8,867 (59.4%)	Ref	Ref	.
Ever user	1,427 (46.1%)	6,070 (40.6%)	1.26 (1.16,1.37)	1.18 (1.08,1.30)	<0.01
1-12 prescriptions	610 (19.7%)	2,547 (17.1%)	1.28 (1.16,1.43)	1.23 (1.10,1.37)	<0.01
>12 prescriptions	817 (26.4%)	3,523 (23.6%)	1.24 (1.12,1.36)	1.14 (1.02,1.27)	0.02
Benzodiazepines					
Never user	2,772 (89.5%)	13,340 (89.3%)	Ref	Ref	.
Ever user	326 (10.5%)	1,597 (10.7%)	0.97 (0.85,1.11)	0.93 (0.81,1.06)	0.25
1-12 prescriptions	227 (7.3%)	1,049 (7.0%)	1.05 (0.90,1.22)	1.01 (0.87,1.18)	0.89
>12 prescriptions	99 (3.2%)	548 (3.7%)	0.83 (0.67,1.04)	0.78 (0.62,0.97)	0.03
Calcium channel blockers					
Never user	2,388 (77.1%)	11,860 (79.4%)	Ref	Ref	.
Ever user	710 (22.9%)	3,077 (20.6%)	1.14 (1.04,1.26)	1.10 (0.99,1.22)	0.08
1-12 prescriptions	256 (8.3%)	1,178 (7.9%)	1.08 (0.93,1.25)	1.04 (0.90,1.21)	0.57
>12 prescriptions	454 (14.7%)	1,899 (12.7%)	1.19 (1.06,1.33)	1.14 (1.00,1.29)	0.04
Nitrates					
Never user	2,591 (83.6%)	12,900 (86.4%)	Ref	Ref	.
Ever user	507 (16.4%)	2,037 (13.6%)	1.24 (1.11,1.38)	1.18 (1.04,1.35)	0.01
1-12 prescriptions	311 (10.0%)	1,162 (7.8%)	1.33 (1.17,1.52)	1.29 (1.11,1.50)	<0.01
>12 prescriptions	196 (6.3%)	875 (5.9%)	1.10 (0.93,1.30)	1.02 (0.84,1.23)	0.86
β <sub>2</sub> agonists					
Never user	2,590 (83.6%)	13,003 (87.1%)	Ref	Ref	.
Ever user <sup>b</sup>	508 (16.4%)	1,934 (12.9%)	1.32 (1.19,1.48)	1.24 (1.05,1.46)	0.01
1-12 prescriptions <sup>b</sup>	272 (8.8%)	1,004 (6.7%)	1.37 (1.19,1.58)	1.27 (1.07,1.51)	<0.01
>12 prescriptions <sup>b</sup>	236 (7.6%)	930 (6.2%)	1.27 (1.10,1.48)	1.13 (0.90,1.43)	0.29
Xanthines					
Never user	3,053 (98.5%)	14,797 (99.1%)	Ref	Ref	.
Ever user <sup>b</sup>	45 (1.5%)	140 (0.9%)	1.55 (1.10,2.18)	1.31 (0.91,1.88)	0.14
1-12 prescriptions <sup>b</sup>	27 (0.9%)	63 (0.4%)	2.13 (1.35,3.36)	1.75 (1.09,2.80)	0.02
>12 prescriptions <sup>b</sup>	18 (0.6%)	77 (0.5%)	1.09 (0.65,1.83)	0.95 (0.55,1.62)	0.85

<sup>a</sup>Calculated using conditional logistic regression, with age, gender, location of residence (deprivation level) and year of diagnosis were accounted for by matched design, and adjustment for acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, rheumatoid arthritis, chronic kidney disease, liver disease, statins and aspirin.

<sup>b</sup>Additional adjustment for steroid-based inhalers

LOS = lower oesophageal sphincter